Drug intelligence / Profile preview

LM-2417 + docetaxel

Development stage: Unknown
Lead developer: LaNova Medicines
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

LM-2417 + docetaxel is an investigational combination therapy under evaluation for advanced solid tumors. LM-2417 is a bispecific antibody developed by LaNova Medicines, acting as a sodium-dependent phosphate transport protein 2B (NaPi-2b) inhibitor. Docetaxel is a well-established small molecule antineoplastic agent that promotes microtubule stabilization, inhibiting cell division. The combination aims to enhance antitumor activity through complementary mechanisms: LM-2417 targets NaPi-2b-expressing tumor cells, while docetaxel disrupts microtubule dynamics, inducing apoptosis and cell cycle arrest. Clinical studies are assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of LM-2417 administered with docetaxel in patients with advanced malignant solid neoplasms[1][3][5][7][9].

Other names: LM-2417 + docetaxel

Targets

SLC34A2 (Sodium-dependent phosphate transporter type IIb)TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on LM-2417 + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM-2417 + docetaxel.

Explore the full profile